Simplex Trading
ADCT icon

Simplex Trading’s ADC Therapeutics ADCT Stock Holding History

Simplex Trading’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.63K Sell
700
-1,400
-67% -$5.52K ﹤0.01% 8266
2025
Q4 		$7.41K Sell
2,100
-20,500
-91% -$83.2K ﹤0.01% 7184
2025
Q3 		$90K Sell
22,600
-10,300
-31% -$32.5K ﹤0.01% 5864
2025
Q2 		$88K Buy
+32,900
New +$69.2K ﹤0.01% 5358
2025
Q1 		– Sell
-4,300
Closed -$8K – 8388
2024
Q4 		$8K Buy
4,300
+600
+16% +$1.57K ﹤0.01% 7296
2024
Q3 		$11K Sell
3,700
-800
-18% -$2.52K ﹤0.01% 7101
2024
Q2 		$14K Buy
4,500
+1,900
+73% +$7.55K ﹤0.01% 7155
2024
Q1 		$11K Buy
+2,600
New +$9.59K ﹤0.01% 7516
2023
Q1 		– Sell
-2,300
Closed -$8K – 8887
2022
Q4 		$8K Sell
2,300
-18,300
-89% -$73.2K ﹤0.01% 7697
2022
Q3 		$99K Buy
+20,600
New +$149K ﹤0.01% 5541
2022
Q2 		– Sell
-1,200
Closed -$17K – 9822
2022
Q1 		$17K Buy
1,200
+1,000
+500% +$15.9K ﹤0.01% 8390
2021
Q4 		$4K Sell
200
-400
-67% -$9.64K ﹤0.01% 9629
2021
Q3 		$14K Hold
600
– – ﹤0.01% 8703
2021
Q2 		$14K Buy
600
+574
+2,208% +$13.3K ﹤0.01% 8857
2021
Q1 		$63K Buy
+26
New +$753 ﹤0.01% 6327

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Simplex Trading's ADCT Position: Q1 2026 in Review

Simplex Trading sold out of ADC Therapeutics (ADCT) in Q1 2026, closing a stake of 2,687 shares — an estimated $10.6K sold.

Simplex Trading first reported a position in ADCT in Q3 2020 and held it in 17 quarters. The position peaked at $66K in Q1 2024. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Simplex Trading reported no remaining ADC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Simplex Trading sold 2,687 ADC Therapeutics shares in Q1 2026, an estimated $10.6K.
  • Simplex Trading first reported a position in ADC Therapeutics in Q3 2020 and held it in 17 quarters.
  • Simplex Trading's ADC Therapeutics position peaked at $66K in Q1 2024.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.